Skip to main content

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Active, not recruiting · Phase 3 · NCT03522246

Conditions: Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed, FIGO Stage III-IV, Partial Response, Complete Response

At a glance

Research payments reported, 2025
$353,399
U.S. investigators named
37
Sites paid
38
Planned or actual enrollment
1,097

About the trial

Sponsor
pharmaand GmbH (with Bristol-Myers Squibb, Gynecologic Oncology Group, European Network of Gynaecological Oncological Trial Groups (ENGOT), Foundation Medicine)
Tested
Rucaparib (drug), Nivolumab (drug), Placebo Oral Tablet (drug), Placebo IV Infusion (drug)
Dates
Started 2018-05-14; completion 2030-12-30
Results posted
Yes

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.

From ClinicalTrials.gov, last updated 2025-06-24. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Pharmaand GmbH reported $353,399 in research payments for this study in 2025 (121 payments).

Products named: Rubraca

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.